The financials
Halozyme Therapeutics, Inc. by the numbers
Halozyme Therapeutics, Inc. (HALO) reported revenue of $377M in Q1 2026 (quarter ended Mar 31, 2026), up 42% from the same quarter a year earlier. That came with a gross margin of 79% and net income of $150M (40% of revenue). For the full year FY2025, revenue was $1.40B (+38% year on year) and net income $317M. Its largest product in Jun 2026 was Royalty at $308M, 59% of the disclosed total, well ahead of Bulk R Hu PH20 at 11%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $377M | $265M | +42% |
| Gross profit | $297M | $216M | +37% |
| Operating income | $185M | $142M | +30% |
| Net income | $150M | $118M | +27% |
| Diluted EPS | $1.22 | $0.93 | +31% |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $308M | 59% |
| Bulk R Hu PH20 | $60M | 11% |
| Proprietary Products Sales | $55M | 11% |
| Collaborative Agreements | $44M | 8.3% |
| Upfront Fees | $36M | 6.8% |
| Device Partnered Products | $15M | 2.8% |
| Event Based Development And Regulatory Milestone And Other Fees | $5.7M | 1.1% |
| Device Licensing And Development | $2.5M | 0.5% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $524.7M (+37%)
Bulk R Hu PH20 grew +156% year on yearSales Based Milestone -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$307.7M$307.7MQoQ +28%year on year +50%+28%+50%
- Bulk R Hu PH20$59.6M$59.6MQoQ -19%year on year +156%-19%+156%
- Proprietary Products Sales$55.4M$55.4MQoQ +32%year on year +19%+32%+19%
- Collaborative Agreements$43.7M$43.7MQoQ +679%year on year +13%+679%+13%
- Upfront Fees$35.5M$35.5MQoQ -year on year ---
- Device Partnered Products$14.6M$14.6MQoQ -3.1%year on year +24%-3.1%+24%
- Event Based Development And Regulatory Milestone And Other Fees$5.7M$5.7MQoQ -year on year -77%--77%
- Device Licensing And Development$2.5M$2.5MQoQ -56%year on year -39%-56%-39%
- Sales Based Milestone$0.00$0.00QoQ -year on year -100%--100%